Your browser is no longer supported. Please, upgrade your browser.
Settings
GALE Galena Biopharma, Inc. daily Stock Chart
GALE [NASD]
Galena Biopharma, Inc.
Index- P/E- EPS (ttm)-0.26 Insider Own0.43% Shs Outstand171.05M Perf Week13.82%
Market Cap295.92M Forward P/E- EPS next Y-0.24 Insider Trans0.00% Shs Float171.05M Perf Month20.98%
Income-43.80M PEG- EPS next Q-0.08 Inst Own15.60% Short Float12.94% Perf Quarter108.43%
Sales- P/S- EPS this Y-5.90% Inst Trans3.62% Short Ratio9.95 Perf Half Y14.57%
Book/sh0.07 P/B24.71 EPS next Y17.20% ROA- Target Price3.90 Perf Year10.19%
Cash/sh0.20 P/C8.53 EPS next 5Y- ROE- 52W Range0.59 - 2.39 Perf YTD17.69%
Dividend- P/FCF- EPS past 5Y17.90% ROI- 52W High-27.62% Beta1.85
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low193.22% ATR0.11
Employees22 Current Ratio0.90 Sales Q/Q- Oper. Margin- RSI (14)67.45 Volatility7.19% 8.26%
OptionableYes Debt/Eq0.30 EPS Q/Q-19.60% Profit Margin- Rel Volume0.44 Prev Close1.70
ShortableYes LT Debt/Eq0.00 EarningsMay 10 AMC Payout- Avg Volume2.22M Price1.73
Recom1.80 SMA2023.09% SMA5025.56% SMA20028.54% Volume979,008 Change1.76%
Dec-22-15Reiterated Maxim Group Buy $7 → $4
Dec-08-15Upgrade Cantor Fitzgerald Sell → Hold
Nov-12-15Upgrade Oppenheimer Perform → Outperform $4
Nov-10-15Reiterated ROTH Capital Buy $8 → $6
Sep-09-15Initiated Raymond James Outperform
Mar-09-15Reiterated Needham Buy $7 → $4
Nov-20-14Reiterated MLV & Co Buy $3 → $5
Aug-22-14Reiterated MLV & Co Buy $5 → $3.50
Aug-12-14Reiterated Needham Buy $9 → $7
Feb-03-14Reiterated Noble Financial Buy $4 → $6
Jan-21-14Reiterated Maxim Group Buy $9 → $11
Jan-08-14Reiterated Maxim Group Buy $6 → $9
Nov-26-13Initiated Oppenheimer Outperform $6
Mar-25-13Initiated Needham Buy $3.50
Nov-28-12Initiated Aegis Capital Buy $6
Nov-05-12Initiated Maxim Group Buy $5
Oct-25-12Initiated MLV & Co Buy $6
Jun-04-12Initiated Cantor Fitzgerald Buy $4
May-24-16 07:05AM  Galena Biopharma to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum GlobeNewswire
May-19-16 01:04PM  GALENA BIOPHARMA, INC. Financials
12:15PM  Galena Biopharma to Present GALE-401 Combined Safety Data at the European Hematology Association 21st Congress GlobeNewswire
May-18-16 05:45PM  Galena Biopharma to Present the GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016 GlobeNewswire +12.98%
May-11-16 02:15AM  Edited Transcript of GALE earnings conference call or presentation 10-May-16 9:00pm GMT -7.25%
May-10-16 05:30PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F
04:56PM  Galena Biopharma reports 1Q loss
04:10PM  Galena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate Update GlobeNewswire
07:07AM  Q1 2016 Galena Biopharma Inc Earnings Release - After Market Close
Apr-27-16 07:05AM  Galena Biopharma to Report First Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, May 10, 2016 GlobeNewswire
Apr-26-16 05:19PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
09:08AM  Galena Biopharma Inducts Mary Ann Gray To Its Board
07:05AM  Galena Biopharma Appoints Mary Ann Gray, Ph.D., to Its Board of Directors GlobeNewswire
Apr-19-16 09:05AM  Galena Biopharma Presents GALE-301/GALE-302 Clinical Booster Data at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Apr-07-16 12:42PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events
09:30AM  Biotech Volatility Both Good And Bad Accesswire
Apr-06-16 03:03PM  The Single Reason Why Galena Biopharma, Inc. Rallied 67% in March at Motley Fool -9.04%
Apr-04-16 02:27PM  These 4 Healthcare Stocks Are All Soaring Today, and Here's Why at Motley Fool +17.45%
09:00AM  Biotech Companies That Are Progressing Rapidly Accesswire
Apr-03-16 09:00AM  Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena at TheStreet
Mar-30-16 04:55PM  Why Galena Biopharma Inc PRESENTed a Higher Stock Price at Motley Fool +13.11%
10:20AM  Is Propanc Health Group the Next Breakthrough Biotech Company Accesswire
08:15AM  Galena Biopharma (GALE) Catches Eye: Stock Moves Up 15.1%
Mar-29-16 12:42PM  Heres Why Galena Biopharma (GALE) Stock is Spiking Today at TheStreet +15.09%
07:05AM  Galena Biopharma Phase 3 PRESENT Clinical Trial with NeuVax (nelipepimut-S) Achieves 70th Qualifying Disease Free Survival Event GlobeNewswire
Mar-23-16 12:32PM  Best Stocks to Buy Today Wednesday March 23, 2016 Accesswire +9.52%
Mar-11-16 03:11PM  GALENA BIOPHARMA, INC. Files SEC form 10-K/A, Annual Report
02:24PM  Edited Transcript of GALE earnings conference call or presentation 10-Mar-16 10:00pm GMT
02:17PM  Galena Not Named Target of Federal Criminal Probe Into Painkiller Use at TheStreet
01:57PM  Galena Biopharma Corrects Error in Form 10-K GlobeNewswire
Mar-10-16 06:41PM  Galena Biopharma reports 4Q loss -6.32%
04:54PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F
04:10PM  Galena Biopharma Reports Fourth Quarter and Year End 2015 Financial Results and Provides a Corporate Update GlobeNewswire
10:57AM  Galena Biopharma (GALE) Shares March Higher, Can It Continue?
07:07AM  Q4 2015 Galena Biopharma Inc Earnings Release - After Market Close
Mar-07-16 07:05AM  Galena Biopharma to Present at the 28th Annual ROTH Conference
Mar-03-16 08:00AM  The Rosen Law Firm, P.A and Pomerantz LLP Announce Proposed Settlement of Galena Biopharmaceutical Securities Litigation - GALE GlobeNewswire
Feb-29-16 05:00AM  Past Winner Spotlight: ENDV, PPCH, EYES, LPCN, GALE Accesswire
Feb-26-16 07:05AM  Galena Biopharma to Report Fourth Quarter and Year End 2015 Financial Results and Provide a Corporate Update on Thursday, March 10, 2016 GlobeNewswire
Feb-25-16 05:26PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan
Feb-16-16 05:17PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
05:00PM  Galena Biopharma Announces Proposed Settlement of Derivative Litigation GlobeNewswire
Feb-08-16 07:05AM  Galena Biopharma Announces Notice of Allowance of U.S. Patent for NeuVax (nelipepimut-S) GlobeNewswire
Feb-02-16 07:05AM  Galena Biopharma to Present at the BIO CEO & Investor Conference GlobeNewswire
Jan-21-16 04:10PM  Galena Biopharma Presents Observational Study Data in Gastric Cancer Patients at the ASCO 2016 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-13-16 01:37PM  Galena Biopharma 2016 Outlook Focuses On 'High Value' Cancer Immunotherapy Pipeline -7.41%
07:05AM  Galena Biopharma Provides 2016 Outlook GlobeNewswire
Jan-11-16 07:05AM  Galena Biopharma to Present at NobleCon12 - Noble Financial Capital Markets Twelfth Annual Investor Conference GlobeNewswire
Jan-07-16 04:51PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -27.91%
12:33PM  Why Are These Stocks Losing Ground Today? at Insider Monkey
09:25AM  Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire
Jan-06-16 04:26PM  Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire -6.52%
Dec-31-15 12:31PM  Galena Biopharma Sells Zuplenz to Focus on Cancer Pipeline
Dec-30-15 07:21PM  Tax-Loss Selling: 1 Stock We'd Be Glad to Sell Right Now at Motley Fool
02:00AM  Midatech Completes Acquisition of Zuplenz® GlobeNewswire
Dec-29-15 08:57AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition
Dec-27-15 09:12AM  This Is the Most Effective Way to Treat Lung Cancer, Study Shows at Motley Fool
Dec-24-15 08:36AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
08:05AM  Market Influences That Drive Equities Forward - New Research on Galena Biopharma, XBiotech, KEMET and Control4 Accesswire
07:05AM  Galena Biopharma Announces a Change to Its Board of Directors GlobeNewswire
Dec-23-15 07:35AM  Morning Movers: Celgene Jumps on Patent Settlement; Finish Line Gains on Upgrade at Barrons.com
Dec-22-15 04:42PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events
Dec-18-15 08:35AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib
07:05AM  Galena Biopharma to Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture of Commercial Operations GlobeNewswire
02:00AM  Midatech Agrees to Acquire Marketed Oncology Product, Zuplenz®, From Galena Biopharma, Inc. GlobeNewswire
Dec-14-15 08:54AM  Galena Biopharma (GALE): Strong Industry, Solid Earnings Estimate Revisions
Dec-11-15 04:47PM  CFO Moves: MSA Safety, Galena Biopharma at The Wall Street Journal
07:58AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
07:39AM  Galena Biopharma Gives Shareholders 3 More Reasons to Bury Their Heads in the Sand at Motley Fool
07:05AM  Galena Biopharma Announces Departure of Chief Financial Officer GlobeNewswire
Dec-08-15 07:05AM  Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire
Dec-04-15 07:24AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:05AM  Galena Biopharma Announces Settlement of Securities Class Action and Shareholder Derivative Lawsuits GlobeNewswire
Nov-30-15 07:05AM  Galena Biopharma to Present at the Oppenheimer 26th Annual Healthcare Conference GlobeNewswire
Nov-29-15 02:43PM  QCR Holdings, Inc. (QCRH): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-24-15 08:25AM  Market Data on Movers and Shakers - Research on HomeTrust Bancshares, Liquidity Services, Galena Biopharma and Hovnanian Enterprises Accesswire
Nov-22-15 03:52PM  Is Galena Biopharma Inc (GALE) A Good Stock To Buy? at Insider Monkey
Nov-20-15 03:03PM  3 Things Galena Biopharma Inc. Wants You to Know at Motley Fool
07:21AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defi
07:05AM  Galena Biopharma Completes Divestiture of Abstral(R) (fentanyl) Sublingual Tablets as Part of Strategic Focus on Its Immunotherapy Pipeline GlobeNewswire
Nov-16-15 08:25AM  Equity Price Movement at a Glance - Research on Gladstone Commercial, Liquidity Services, Galena Biopharma and Hovnanian Enterprises Accesswire
Nov-12-15 09:06AM  Galena Biopharma (GALE) Stock Rating Upgraded at Oppenheimer at TheStreet
Nov-11-15 04:42PM  Galena Biopharma's 3rd-Quarter Report Is Nothing Short of Bizarre at Motley Fool
Nov-10-15 12:56PM  Here's Why Galena Biopharma's Stock Tanked Today at Motley Fool -11.05%
12:27PM  Galena Biopharma (GALE) Stock Declines on Earnings Miss at TheStreet
12:24AM  Edited Transcript of GALE earnings conference call or presentation 9-Nov-15 10:00pm GMT
Nov-09-15 06:11PM  Galena Biopharma reports 3Q loss
05:00PM  Galena Biopharma Inc Earnings Call scheduled for 5:00 pm ET today
04:48PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F
04:05PM  Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on Its Clinical Development Programs With Planned Divestiture of the Commercial Business GlobeNewswire
07:07AM  Q3 2015 Galena Biopharma Inc Earnings Release - After Market Close
07:05AM  Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting GlobeNewswire
Nov-06-15 02:26PM  4 Questions to Ask Ahead of Galena Biopharma's Third-Quarter Earnings Report at Motley Fool
09:00AM  Is a Surprise Coming for Galena Biopharma (GALE) This Earnings Season?
07:05AM  Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire
Oct-30-15 09:17AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
07:05AM  Galena Biopharma Appoints Bijan Nejadnik, M.D., as Executive Vice President and Chief Medical Officer GlobeNewswire
Oct-27-15 09:05AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events
Oct-26-15 07:05AM  Galena Biopharma to Report Third Quarter Financial Results and Provide Business Update on Monday, November 9, 2015 GlobeNewswire
Oct-22-15 07:05AM  Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax(TM) Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences GlobeNewswire
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs. The company's lead product candidate, NeuVax (nelipepimut-S), is in Phase III clinical trials for the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combination with Herceptin for HER2 1+/2+ node-positive and high-risk node-negative breast cancer treatment; and Phase II clinical trials in combination with trastuzumab for node positive and negative HER2 IHC 3+ patients. It also develops GALE-301 (folate binding protein), which is in Phase IIa clinical trials for the prevention of recurrence in patients with ovarian and endometrial cancers; GALE-302, a version of the E39 peptide that is in Phase 1b clinical trial for investigating a novel vaccination series; and GALE-401 (anagrelide controlled release), which is in a Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. Galena Biopharma, Inc. has strategic development and commercialization partnership with Dr. Reddy's Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in San Ramon, California.